MTEM - スレッシュ・ホ―ルド・ファ―マス―ティカルズ (Molecular Templates Inc.)

MTEMのニュース

   DZ Bank likes Medtronic in premarket analyst action  2020/03/25 11:14:36 Seeking Alpha
Menlo Therapeutics (NASDAQ:MNLO) initiated with Overweight rating and $8 (161% upside) price target at Barclays. Molecular Templates (NASDAQ:MTEM) initiate
   The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study  2020/03/06 13:49:43 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit hit 52-week highs March 5.) Arcus Biosciences Inc (NYSE: RCUS ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Centogene NV (NASDAQ: CNTG ) Cue Biopharma Inc (NASDAQ: CUE ) Forty Seven Inc (NASDAQ: FTSV ) Inovio Pharmaceuticals Inc (NASDAQ: INO ) Molecular Templates Inc (NASDAQ: MTEM ) Natera Inc (NASDAQ: NTRA ) Ocular Therapeutix Inc (NASDAQ: OCUL ) (Piper Sandler lifted the price target for the shares from $7 to $11) Quest Diagnostics Inc (NYSE: DGX ) (announced plans to launch a COVID-19 test service) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Syndax Pharmaceuticals Inc (NASDAQ: SNDX ) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 5.) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANI Pharmaceuticals Inc Common Stock (NASDAQ: ANIP ) Aytu Bioscience Inc (NASDAQ: AYTU ) Celcuity Inc (NASDAQ: CELC ) Chembio Diagnostics Inc (NASDAQ: CEMI ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Enlivex Therapeutics Ltd (NASDAQ: ENLV ) Evogene Ltd (NASDAQ: EVGN ) EXACT Sciences Corporation (NASDAQ: EXAS ) Glaukos Corp (NYSE: GKOS ) Lantheus Holdings Inc (NASDAQ: LNTH ) Mylan NV (NASDAQ: MYL ) Neurometrix Inc (NASDAQ: NURO ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Orthofix Medical Inc (NASDAQ: OFIX ) Passage Bio Inc (NASDAQ: PASG ) (went public last week) Polarityte Inc (NASDAQ: PTE ) STRATA Skin Sciences Inc (NASDAQ: SSKN ) SurModics, Inc. (NASDAQ: SRDX ) (reacted to first-quarter results) T2 Biosystems Inc (NASDAQ: TTOO ) Xeris …
   MTEM urges new govt to intensify Bumiputera empowerment agenda  2020/03/04 03:25:38 The Sun Daily
KUALA LUMPUR : The Malay Economic Action Council (MTEM) wants Shared Prosperity Vision 2030 (SPV2030), which will be continued under the new government led by Prime Minister Tan Sri Muhyiddin Yassin, to address economic disparities between the races and create a high-value economy. Chief executive officer Ahmad Yazid Othman said the Bumiputera economic community is hoping that the Bumiputera empowerment agenda will be stepped up under the new administration. “Several Bumiputera achievement targets need to be reviewed, and the government should implement quickly development projects to mobilise the economy based on a Bumiputera master policy under SPV2030, instead of continuing the austerity drive which is only to demonstrate political messages but does not benefit the country and the people. “Do not let the market forces philosophy to dictate the country’s fate. We have to accept the need for state intervention so that the quality of life of all Malaysians, especially Bumiputeras, can be improved swiftly,” he said in a statement tonight.
   The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs  2020/02/06 12:47:50 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 5.) Alector Inc (NASDAQ: ALEC ) (announced granting of Fast Track Designation to its AL101 for the treatment of patients with frontotemporal dementia) Arvinas Inc (NASDAQ: ARVN ) Ascendis Pharma A/S (NASDAQ: ASND ) Biogen Inc (NASDAQ: BIIB ) (won patent challenge on multiple sclerosis drug Tecfidera) BioXcel Therapeutics Inc (NASDAQ: BTAI ) (announced FDA clearance of IND for BXCL501 to treat opioid withdrawal symptoms) ChemoCentryx Inc (NASDAQ: CCXI ) Eli Lilly And Co (NYSE: LLY ) Insmed Incorporated (NASDAQ: INSM ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Insulet Corporation (NASDAQ: PODD ) Johnson & Johnson (NYSE: JNJ ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) Molecular Templates Inc (NASDAQ: MTEM ) Novo Nordisk A/S (NYSE: NVO ) (reacted to quarterly results ) Profound Medical Corp (NASDAQ: PROF ) (announced retirement of bank debt ahead of schedule) PTC Therapeutics, Inc (NASDAQ: PTCT ) Quest Diagnostics Inc (NYSE: DGX ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) Repligen Corporation (NASDAQ: RGEN ) ResMed Inc. (NYSE: RMD ) Revance Therapeutics Inc (NASDAQ: RVNC ) Theravance Biopharma Inc (NASDAQ: TBPH ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 5.) Endologix, Inc. (NASDAQ: ELGX ) Salarius Pharmaceuticals Inc (NASDAQ: SLRX ) Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH ) See also: The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus Stocks In Focus Sanofi's Multiple Sclerosis Drug Aces Midstage Trial; Q4 Sales, Net Income Rise Sanofi SA (NASDAQ: SNY ) said a Phase 2b study that evaluated its investigational BTK inhibitor SAR442168 for multiple sclerosis met the primary endpoint, …
   The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data  2020/02/05 12:43:12 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 4) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ALEC ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Applied Therapeutics Inc (NASDAQ: APLT ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT )(IPOed Jan. 31) Black Diamond Therapeutics Inc (NASDAQ: BDTX )(IPOed Jan. 30) ChemoCentryx Inc (NASDAQ: CCXI ) Eli Lilly And Co (NYSE: LLY ) Fate Therapeutics Inc (NASDAQ: FATE ) Frequency Therapeutics Inc (NASDAQ: FREQ ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Hologic, Inc. (NASDAQ: HOLX ) Insmed Incorporated (NASDAQ: INSM )(reacted to positive analyst actions following a positive data readout reported Monday) Insulet Corporation (NASDAQ: PODD ) Johnson & Johnson (NYSE: JNJ ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) Molecular Templates Inc (NASDAQ: MTEM ) Neoleukin Therapeutics Inc (NASDAQ: NLTX ) PTC Therapeutics, Inc (NASDAQ: PTCT ) Quest Diagnostics Inc (NYSE: DGX ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) Repligen Corporation (NASDAQ: RGEN ) ResMed Inc.
   Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus  2019/12/29 23:38:06 Benzinga
Biotech stocks advanced in the penultimate week of the year, and the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) is on track to end the year with gains in excess of 25%. The previous week saw FDA announcements on verdicts for several therapeutic options. Notable among the therapeutic options that crossed the FDA hurdle were Allergan plc (NYSE: AGN )'s migraine drug; Flexion Therapeutics Inc (NASDAQ: FLXN )'s Zilretta, which was given a label expansion; Intra-Cellular Therapies Inc (NASDAQ: ITCI )'s schizophrenia drug; and two generics for Eliquis, a blood thinner marketed by Bristol-Myers Squibb Co (NYSE: BMY ) and Pfizer Inc. (NYSE: PFE ). However, Correvio Pharma Corp (NASDAQ: CORV )'s Brinavess, a drug to treat atrial fibrillation, stumbled at the FDA altar. A big gene therapy collaboration agreement between Roche Holdings AG Basel ADR (OTC: RHHBY ) and Sarepta Therapeutics Inc (NASDAQ: SRPT ) was announced. The following are key biotech catalysts for the unfolding week: PDUFA Dates The FDA is scheduled to rule on the pancreatic cancer drug candidate lynparza, which is being co-developed by AstraZeneca plc (NYSE: AZN ) and Merck & Co., Inc. (NYSE: MRK ).
   The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen  2019/11/27 12:26:05 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 26) Allakos Inc (NASDAQ: ALLK ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Ardelyx Inc (NASDAQ: ARDX ) ( announced a research collaboration with Japan's Kyowa Kirin and an investment in the company by the latter) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR )(reacted to its full-year results) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) ChemoCentryx Inc (NASDAQ: CCXI )( announced positive late-stage results for rare inflammation disease drug) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Global Blood Therapeutics Inc (NASDAQ: GBT )(announced FDA nod for sickle cell disease drug) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Globus Medical Inc (NYSE: GMED ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Merck & Co., Inc. (NYSE: MRK )(Keytruda was approved in China as a first-line treatment for lung cancer, in combination with chemotherapy) Molecular Templates Inc (NASDAQ: …
   The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug  2019/11/26 13:06:41 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) (Guggenheim initiated coverage of stock with Buy rating and $50 price target) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) (announced achievement of enrollment target in a Phase 3 trial of drug to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) BioNTech SE – ADR (NASDAQ: BNTX ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Epizyme Inc (NASDAQ: EPZM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Globus Medical Inc (NYSE: GMED ) Halozyme Therapeutics, Inc.
   The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate  2019/11/22 13:18:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) (raised full-year guidance following completion of Otezla purchase from Celgene) Antares Pharma Inc (NASDAQ: ATRS ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cue Biopharma Inc (NASDAQ: CUE ) Epizyme Inc (NASDAQ: EPZM ) Kamada Ltd. (NASDAQ: KMDA ) Kodiak Sciences Inc (NASDAQ: KOD ) Molecular Templates Inc (NASDAQ: MTEM ) Recro Pharma Inc (NASDAQ: REPH ) (completed spin-off of Baudax Bio in a bid to a become a pure play CDMO) Down In The Dumps (Biotech stocks that hit 52-week lows on Nov. 21.) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) (received European approval for its Rhokiinsa 0.02% for the reduction of elevated intraocular pressure) Affimed NV (NASDAQ: AFMD ) Anixa Biosciences Inc (NASDAQ: ANIX ) CareDx Inc (NASDAQ: CDNA ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Genprex Inc (NASDAQ: GNPX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Interpace Biosciences Inc (NASDAQ: IDXG ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its previously announced common stock offering) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) MacroGenics Inc (NASDAQ: MGNX ) Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) Neon Therapeutics Inc (NASDAQ: NTGN ) (announced a changed focus and the elimination of 24% of workforce) Novavax, Inc. (NASDAQ: NVAX ) Nuvectra Corp (NASDAQ: NVTR ) Onconova Therapeutics …
   Analysts Estimate Molecular Templates (MTEM) to Report a Decline in Earnings: What to Look Out for  2019/08/01 14:33:08 Zacks Investment Research
Molecular Templates (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Molecular Templates reports Q4 results  2019-03-28
Molecular Templates (NASDAQ: MTEM ): Q4 GAAP EPS of $0.18. More news on: Molecular Templates, Inc., Earnings news and commentary, Healthcare stocks news, , Read more …
   Molecular Templates launches mid-stage study of MT-3724 in DLBCL  2019-03-28
Molecular Templates ( MTEM +0.7% ) initiates a Phase 2 clinical trial evaluating MT-3724 in up to 100 patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two prior lines of therapy. More news on: Molecular Templates, Inc., Healthcare stock…

calendar